Skip to main content

End Stage Renal Disease clinical trials at UC Irvine

3 in progress, 1 open to eligible people

Showing trials for
  • TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done

    Orange 5379513, California 5332921 and other locations

  • Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

    Sorry, in progress, not accepting new patients

    The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access

    Irvine 5359777, California 5332921 and other locations

  • Tegoprubart in Patients Undergoing Kidney Transplantation

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

    Orange 5379513, California 5332921 and other locations

Last updated: